Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 3/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | NPC1 | O15118 | 2/20 | 0.43 |
| ▸ | RAB9A | P51151 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.42 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.42 |
| ▸ | KCNA5 | P22460 | 2/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | RECQL | P46063 | 1/20 | 0.41 |
| ▸ | CASP3 | P42574 | 1/20 | 0.40 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.40 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.40 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30523061 | 1.00 | KMT2A (0.46) | KMT2AALDH1A1MAPTPOLBMEN1 | |
| SCHEMBL3655233 | 0.84 | KMT2A (0.47) | KMT2AALDH1A1MAPTPOLBMEN1 | |
| SCHEMBL13523030 | 0.83 | MMP8 (0.45) | ALDH1A1MAPTGAAKDM4EMAPK1 | |
| SCHEMBL10676737 | 0.83 | KMT2A (0.46) | KMT2AALDH1A1MEN1PTGS1PTGS2 | |
| SCHEMBL1133808 | 0.83 | PTGS1 (0.60) | KMT2AALDH1A1MAPTPOLBNPC1 | |
| SCHEMBL1525657 | 0.83 | KMT2A (0.46) | KMT2AALDH1A1MAPTPOLBMEN1 | |
| SCHEMBL30489976 | 0.83 | PTGS1 (0.60) | KMT2AALDH1A1MAPTPOLBNPC1 | |
| SCHEMBL14624428 | 0.83 | PTGS1 (0.60) | KMT2AALDH1A1MAPTPOLBNPC1 | |
| SCHEMBL4960148 | 0.81 | KMT2A (0.44) | KMT2AALDH1A1MAPTPOLBMEN1 | |
| SCHEMBL18890143 | 0.81 | ALDH1A1 (0.48) | KMT2AALDH1A1MAPTPOLBMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250282749-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. | 2025-09-11 | — | — | US | disclosed |
| EP-4469445-A1 | COMPOUNDS AND METHODS OF USE | Tango Therapeutics, Inc. (US) | 2024-12-04 | — | — | EP | disclosed |
| US-11753405-B2 | 1,3,4-thiadiazole compounds and their use in treating cancer | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2023-09-12 | — | — | US | disclosed |
| US-11753405-B2 | 1,3,4-thiadiazole compounds and their use in treating cancer | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2023-09-12 | — | — | US | disclosed |
| US-11753405-B2 | 1,3,4-thiadiazole compounds and their use in treating cancer | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2023-09-12 | — | — | US | disclosed |
| WO-2023146991-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. (US) | 2023-08-03 | — | — | WO | disclosed |
| WO-2023146991-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. (US) | 2023-08-03 | — | — | WO | disclosed |
| WO-2023066357-A1 | FUSED CYCLIC COMPOUNDS, PREPARATION METHOD THEREFOR, AND MEDICAL USE THEREOF | 江苏恒瑞医药股份有限公司 | 2023-04-27 | — | — | WO | disclosed |
| EP-3383873-B1 | 1,3,4-THIADIAZOLE COMPOUNDS AND THEIR USE IN TREATING CANCER | CANCER RESEARCH TECH LTD (GB) | 2022-03-09 | — | — | EP | disclosed |
| CN-108349966-B | 1,3, 4-thiadiazole compounds and their use in the treatment of cancer | 阿斯利康(瑞典)有限公司 | 2022-02-15 | — | — | CN | disclosed |
| US-6916805-B2 | Quinoxalinones as serine protease inhibitors | WARNER-LAMBERT COMPANY LLC (US) | 2005-07-12 | — | — | US | disclosed |
| US-20030187256-A1 | Benoxazinones/benzothiazinones as serine protease inhibitors | BERRYMAN KENT ALAN (US) | 2003-10-02 | — | — | US | disclosed |
| US-6509335-B1 | This invention discloses benzoxazinone and benzothiazinone compounds which display inhibitory effects on serine proteases such as factor Xa, thrombin, and/or factor VIIa. The invention also discloses pharmaceutically acceptable salts of | WARNER-LAMBERT COMPANY | 2003-01-21 | — | — | US | disclosed |
| US-20020086866-A1 | Quinoxalinones as serine protease inhibitors | DUDLEY DANETTE ANDREA (US) | 2002-07-04 | — | — | US | disclosed |
| US-6410536-B1 | ANTICOAGULANTS | WARNER-LAMBERT COMPANY | 2002-06-25 | — | — | US | disclosed |
| EP-1068190-A1 | QUINOXALINONES AS SERINE PROTEASE INHIBITORS SUCH AS FACTOR XA AND THROMBIN | WARNER-LAMBERT COMPANY LLC (US) | 2001-01-17 | — | — | EP | disclosed |
| EP-1068191-A1 | BENZOXAZINONES/BENZOTHIAZINONES AS SERINE PROTEASE INHIBITORS | WARNER-LAMBERT COMPANY LLC (US) | 2001-01-17 | — | — | EP | disclosed |
| WO-1999050254-A1 | QUINOXALINONES AS SERINE PROTEASE INHIBITORS SUCH AS FACTOR XA AND THROMBIN | WARNER-LAMBERT COMPANY (US) | 1999-10-07 | — | — | WO | disclosed |
| WO-1999050257-A1 | BENZOXAZINONES/BENZOTHIAZINONES AS SERINE PROTEASE INHIBITORS | WARNER-LAMBERT COMPANY (US) | 1999-10-07 | — | — | WO | disclosed |
| US-5374638-A | Cardiovascular disorders, hypotensive agents | MERCK & CO., INC. (US) | 1994-12-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020086866-A1 | Quinoxalinones as serine protease inhibitors | HABP2, SERPINB1, PRSS1 | KMT2A 2517/4885ALDH1A1 1960/4885MAPT 4000/4885 |
| US-20250282749-A1 | COMPOUNDS AND METHODS OF USE | CYP1B1, CYP2C19, UGT1A1 | KMT2A 4270/4885ALDH1A1 193/4885MAPT 2651/4885 |
| US-11753405-B2 | 1,3,4-thiadiazole compounds and their use in treating cancer | GLS2, GLS, GLUL | KMT2A 580/4885ALDH1A1 233/4885MAPT 4777/4885 |
| US-20030187256-A1 | Benoxazinones/benzothiazinones as serine protease inhibitors | HABP2, SPINT2, SERPINB1 | KMT2A 2288/4885ALDH1A1 2444/4885MAPT 3606/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.